

MYRIAD GENETICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	<u>Twelve Months Ended</u>		<u>Three Months Ended</u>	
	<u>June 30, 2001</u>	<u>June 30, 2000</u>	<u>June 30, 2001</u>	<u>June 30, 2000</u>
REVENUES:				
Research revenue	\$28,071,252	\$25,219,766	\$5,661,695	\$6,428,369
Predictive medicine revenue	17,091,139	8,793,272	5,160,282	2,728,229
Total revenues	45,162,391	34,013,038	10,821,977	9,156,598
COSTS AND EXPENSES:				
Predictive medicine cost of revenue	7,402,906	3,986,473	2,221,517	1,125,875
Research and development expense	33,818,144	28,098,769	7,247,908	7,773,351
Selling, general and administrative expense	17,077,846	13,474,923	4,806,659	3,761,510
Total costs and expenses	58,298,896	45,560,165	14,276,084	12,660,736
Operating loss	(13,136,505)	(11,547,127)	(3,454,107)	(3,504,138)
Other income (expense):				
Interest income	6,850,479	3,208,506	1,372,919	948,891
Other	(305,134)	(383,481)	(22,021)	(8,729)
Net loss before taxes	(6,591,160)	(8,722,102)	(2,103,209)	(2,563,976)
Income taxes	583,333	-	83,333	-
Net loss	<u>(\$7,174,493)</u>	<u>(\$8,722,102)</u>	<u>(\$2,186,542)</u>	<u>(\$2,563,976)</u>
Basic and diluted loss per share	<u>(\$0.31)</u>	<u>(\$0.43)</u>	<u>(\$0.09)</u>	<u>(\$0.12)</u>
Basic and diluted weighted average shares outstanding	<u>22,815,035</u>	<u>20,220,446</u>	<u>23,323,937</u>	<u>21,100,558</u>

SELECTED BALANCE SHEET DATA

	<u>June 30, 2001</u>	<u>June 30, 2000</u>
Cash and investments	\$145,954,968	\$88,655,844
Total assets	\$172,145,355	\$106,375,305
Shareholders' equity	\$139,561,798	\$77,706,647